The historical rank and industry rank for Xenetic Biosciences's Net Margin % or its related term are showing as below:
XBIO'
s Net Margin % Range Over the Past 10 Years
Min: -75147.06 Med: -383.83 Max: -47.4
Current: -70.03
XBIO's Net Margin % is ranked better than 52.01% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs XBIO: -70.03
Xenetic Biosciences (NAS:XBIO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Xenetic Biosciences Net Margin % Related Terms
Xenetic Biosciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xenetic Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (XBIO) has a Net Margin % of -56.51% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #454 out of 946 companies in the Biotechnology industry, placing it in the top 48%.
Is Xenetic Biosciences' Net Margin % too high?
Xenetic Biosciences' current Net Margin % is -56.51%. Based on the distribution chart, Xenetic Biosciences ranks #454 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xenetic Biosciences has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Net Margin % compare to PCSA and SILO?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #454 out of 946 companies for Net Margin %. This puts Xenetic Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Net Margin % is -56.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.18, compared to a current price of $2.95 — trading 29.5% below its estimated fair value. The current Net Margin % is -56.51%. Xenetic Biosciences' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Net Margin % is -56.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $2.95 is trading 29.5% below its estimated GF Value™ of $4.18.
GuruFocus considers Xenetic Biosciences to be Possible Value Trap.
Key valuation signals for XBIO:
Net Margin %: -56.51%
GF Value™: $4.18 vs. price of $2.95 (29.5% below fair value)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
83GF Score
Get the complete analysis for XBIO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
